Stock Track | Teva Pharmaceutical Soars 12.02% Intraday on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track04-29

Teva Pharmaceutical's stock surged 12.02% during intraday trading on Wednesday, driven by the company's better-than-expected first-quarter financial results and a strategic acquisition announcement.

The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst consensus estimates of $0.46 to $0.48. Revenue reached $3.98 billion, also exceeding expectations of approximately $3.79 billion to $3.81 billion. The strong performance was attributed to robust growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year, demonstrating the success of Teva's "Pivot to Growth" strategy.

Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million in cash, adding ecopipam, a first-in-class therapy for Tourette syndrome with positive Phase 3 data, to its neuroscience pipeline. The company maintained its 2026 revenue guidance range of $16.4 billion to $16.8 billion while updating its earnings outlook to reflect the Emalex transaction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192387887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192387887","market":"nz","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Soars 12.02% Intraday on Strong Q1 Earnings Beat and Emalex Acquisition","media":"Stock Track","content":"<p>Teva Pharmaceutical's stock surged 12.02% during intraday trading on Wednesday, driven by the company's better-than-expected first-quarter financial results and a strategic acquisition announcement.</p><p>The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst consensus estimates of $0.46 to $0.48. Revenue reached $3.98 billion, also exceeding expectations of approximately $3.79 billion to $3.81 billion. The strong performance was attributed to robust growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year, demonstrating the success of Teva's \"Pivot to Growth\" strategy.</p><p>Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million in cash, adding ecopipam, a first-in-class therapy for Tourette syndrome with positive Phase 3 data, to its neuroscience pipeline. The company maintained its 2026 revenue guidance range of $16.4 billion to $16.8 billion while updating its earnings outlook to reflect the Emalex transaction.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Soars 12.02% Intraday on Strong Q1 Earnings Beat and Emalex Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Soars 12.02% Intraday on Strong Q1 Earnings Beat and Emalex Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-29 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Teva Pharmaceutical's stock surged 12.02% during intraday trading on Wednesday, driven by the company's better-than-expected first-quarter financial results and a strategic acquisition announcement.</p><p>The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst consensus estimates of $0.46 to $0.48. Revenue reached $3.98 billion, also exceeding expectations of approximately $3.79 billion to $3.81 billion. The strong performance was attributed to robust growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year, demonstrating the success of Teva's \"Pivot to Growth\" strategy.</p><p>Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million in cash, adding ecopipam, a first-in-class therapy for Tourette syndrome with positive Phase 3 data, to its neuroscience pipeline. The company maintained its 2026 revenue guidance range of $16.4 billion to $16.8 billion while updating its earnings outlook to reflect the Emalex transaction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1192387887","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192387887","pubTimestamp":1777473324,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical's stock surged 12.02% during intraday trading on Wednesday, driven by the company's better-than-expected first-quarter financial results and a strategic acquisition...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"个股追踪|梯瓦制药盘中大涨12.02%，因Q1盈利强劲超预期及收购Emalex","themeId":"6b8ec1151d00a58a526cec0791df8857","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical's stock surged 12.02% during intraday trading on Wednesday, driven by the company's better-than-expected first-quarter financial results and a strategic acquisition announcement.The pharmaceutical giant reported adjusted earnings per share of $0.53 for Q1 2026, surpassing analyst consensus estimates of $0.46 to $0.48. Revenue reached $3.98 billion, also exceeding expectations of approximately $3.79 billion to $3.81 billion. The strong performance was attributed to robust growth in key innovative products including AUSTEDO, AJOVY, and UZEDY, which collectively grew by 41% year-over-year, demonstrating the success of Teva's \"Pivot to Growth\" strategy.Additionally, Teva announced a definitive agreement to acquire Emalex Biosciences for $700 million in cash, adding ecopipam, a first-in-class therapy for Tourette syndrome with positive Phase 3 data, to its neuroscience pipeline. The company maintained its 2026 revenue guidance range of $16.4 billion to $16.8 billion while updating its earnings outlook to reflect the Emalex transaction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192387887","isCrawlerRequest":true}